NEW USE OF METAL COMPLEXES HAVING ORGANIC LIGANDS FOR ACTIVATING OLEFIN METATHESIS RUTHENIUM (PRE)CATALYSTS
The invention relates to use of metal complexes containing at least one organic ligand for the activation of the so-called dormant olefin metathesis ruthenium (pre)catalysts. Furthermore, the invention relates to the use of such a catalytic system in a ring opening metathesis polymerization reaction. The synthesis of the carbon-carbon double bond via olefin metathesis is of great importance both in organic synthesis and in the chemical industry. Ruthenium catalysts due to their high stability and durability in the presence of various functional groups are very useful in reactions such as RCM - ring closing metathesis, CM - cross metathesis, ROMP - ring opening metathesis polymerization [ Due to the reaction mechanism and the nature of the resulting product, RCM and CM reactions require (pre)catalysts of a different type than the ROMP polymerization reaction. In case of RCM and CM reactions, fast initiating (pre)catalysts with high conversion rates and selectivity are useful. In ROMP reactions, macromolecular products are formed, so initiators are required that enable to control the polydispersity degree of the resulting polymer. Catalysts showing reduced activity in the presence of monomer at room temperature are used, so-called latent catalysts. One of the advantages of dormant catalysts is the ability to pre-prepare the monomer-(pre)catalyst mixture. Development of stable, well-defined metathesis catalysts has opened new possibilities for metathesis polymerization reactions. Activation of dormant catalysts requires physical stimuli from outside. A dormant (pre)catalyst usually contains a chelating (donor) ligand that "blocks" the coordination site so that the complex shows reduced activity. Activation occurs after dissociation of chelating ligand and exposing the coordination center of the metal. Dissociation of the chelating ligand requires chemical stimulation (most often using an acid (Lewis or Bronsted)), thermal or light having appropriate wavelength. An activating agent is called an activator or a co-catalyst, while an activator-(pre)catalyst system is called a catalytic system. A mixture of monomer and optionally other additives together with the catalytic system is called a formulation. In the prior art chemical activators being Lewis and Bronsted acids have been described, such as: HC1, HBr, HI, CH3COOH , CF3COOH, HCOOH, ZnCl2, CuCl, SnCl2, HBF4 ( Photochemical activation can be accomplished by using acid-activated (pre)catalysts and photoacid generators (PAG). Photoacid generators are usually sulfonium salts. During UV irradiation, an acid particle is released from PAG. Exemplary systems are disclosed in: Examples of thermally activated ruthenium (pre)catalysts for ROMP polymerization are described in: A significant disadvantage of chemical or photochemical activation with PAG is the acid molecule that is released, which can cause corrosion and destruction of moulds. In addition, this type of activation allows only limited control of the initiation rate. Once acid is released, the polymerization reaction takes 1 to 10 minutes. As a result, due to the rapidly increasing viscosity, the time for process (operative) actions is very short (working life). This is related to a mechanism of activation of dormant (pre)catalysts - after the formation of the acid molecule, ligands in the (pre)catalyst are protonated and an active, rapidly initiating metathesis catalyst is formed. A disadvantage of thermal activation is a difficulty of even and rapid heating of the formulation. As a result (and also due to the nature of initiation) the (pre)catalyst does not initiate completely, the effect of which is the appearance of defects resulting from material shrinkage, much larger than in the case of chemical activation. Another problem is a short storage time of the formulation (shelf life), because dormant thermally activated catalysts show low activity even at room temperature, sufficient to solidify/gel the formulation within a period of several minutes to several hours. This means that the polymerization reaction starts before the heat is provided, immediately after the (pre)catalyst is added. Surprisingly it turned out that metal complexes: Ru, Cu, having organic ligands can act as co-catalysts in metathetical polymerization reactions and allow to get very long formulation life times and to control gelling time after activation within a very broad time range (from several seconds to several hours). In the light of the prior art it is not obvious that complexes of general formulae 1a and 1b can act as activators of olefin metathesis ruthenium (pre)catalysts. Activators according to the invention have universal use. Compounds described by general formulae 1a and 1b activate not only "classic" dormant complexes having a chelating ligand - of general formulae 3a-d. They also act as carbene acceptors, and for this reason they can be used to activate (pre)catalysts having two neutral ligands in the coordination sphere ((pre)catalysts of general formula 2). Thus, the subject of the invention is the use of compounds which are:
Preferably, the copper complexes being the activators of olefin metathesis ruthenium (pre)catalysts have the structure described by a general formula 1a: Preferably, the copper complexes being the activators of olefin metathesis ruthenium (pre)catalysts have the structure defined by a general formula 1a: Preferably, the copper complexes being the activators of olefin metathesis ruthenium (pre)catalysts have the structure described by a general formula 1a: Preferably, the activators according to the invention have a structure represented by a structural formula selected from:
Preferably, the olefin metathesis ruthenium (pre)catalyst is described by a general formula 2, 3a, 3b, 3c 3d or 3e:
wherein:
Preferably, the olefin metathesis ruthenium (pre)catalyst is described by a general formula 2, 3a, 3b or 3c:
wherein:
Preferably, the olefin metathesis ruthenium (pre)catalyst is defined by a general formula 2, 3a, 3b or 3c:
wherein:
Preferably, the metathesis ruthenium (pre)catalyst 2 has the structure defined by a general formula 2a or 2b:
wherein:
Preferably, the olefin metathesis ruthenium (pre)catalyst 2 has the structure defined by a general formula 2a:
wherein:
Preferably, the olefin metathesis ruthenium (pre)catalyst has a structure represented by a structural formula selected from:
The invention also relates to the use of copper and ruthenium complexes according to the invention for activating metathesis catalysts in ring opening metathesis polymerization reaction (ROMP). The use of activators according to the invention in the ROMP metathesis reaction allows for obtaining polymers showing better parameters. Materials of higher hardness are obtained (Example 1). In addition, due to the use of activators, it is possible to control the polymerization reaction, via the activators' effect on gelling time and curing time. Preferably, the reaction is carried out at a temperature from 0 to 100°C. Preferably, the reaction is carried out over a period of 1 minute to 24 hours. Preferably, the reaction is carried out with no solvent. Preferably, the catalyst is added in a solid form and/or in form of a solution in an organic solvent, in an amount of not higher than 100 ppm. Preferably, the activator is added in a solid form and/or in form of a solution in an organic solvent, in an amount of not higher than 1000 ppm. Preferably, 4-dimethylaminopyridine in a solid form and/or in form of a solution in an organic solvent is added to the catalyst-activator system in an amount of not higher than 500 ppm. In the present description, the terms used have the meanings. Non-defined terms in this document have meanings that are given and understood by a person skilled in the art in view of her/his best knowledge, the present disclosure and the patent application context. Unless indicated otherwise, the following conventional chemistry terms are used in this description that have the meanings indicated as in the definitions below: The term The term The term The term The term The term The term The term The term The term The term The term The term The following examples are provided solely to illustrate the invention and clarifying its individual aspects, and with no intention to limit it, and should not be identified with its entire scope as defined in the appended claims. Unless otherwise indicated, in the following examples standard materials and methods were used in the art or it was proceeded according to manufacturers' recommendations for specific reagents and methods. Performance of activators 1a1-1a5 and 1b1-1b5 according to the invention: DCPD - ULTRENE 99-6 was purchased from Cymetech Corporation. Complexes 1a1, 1a2 and 1a4 were prepared according to own procedures. Compounds las, 1b3, 1b4 and 1b5 were prepared according to literature procedures [1, 2, 3, 4]. Complexes 1a3, 1b1, 1b2 and olefin metathesis (pre)catalysts and DMAP are commercially available compounds. DCM was dried using 4A-type molecular sieves. Triphenylphosphine (5 g, 19.06 mmol, 2 equivalents) and ethyl acetate (110 mL) were added to a 250 mL round-bottom flask. Further, anhydrous copper chloride(I) (0.94 g, 9.53 mmol, 1 equivalent) was added to the solution. The suspension was stirred for 5 minutes at room temperature. The solid was filtered off on a sintered funnel and washed with two portions of ethyl acetate. DCM was added to the obtained crude product. Most of the solid was dissolved. A small amount of sediment remained. The sediment was filtered off on a sintered funnel. The solvent was evaporated. The product was dried using vacuum pump for several hours. 3.11 g of white powder was obtained, 66% yield. Elemental analysis - calculated for C27H22.5ClCu: C 65.86; H 4.61; found: C 65.92; H 4.62. Anhydrous copper (I) chloride (11.88 g, 120 mmol, 1.2 equivalents) and degassed DCM (100 mL) were added to a 250 mL round-bottom flask. Triethyl phosphite (17.15 mL, 100 mmol, 1 equivalent) was added to the stirred suspension. The reaction was carried out under argon atmosphere for 30 minutes at room temperature. The reaction mixture was filtered through Celite. The solvent was evaporated. The product was dried using a vacuum pump for several hours. 26.36 g of a colorless, odorless oil was obtained, 44% yield. Airsensitive compound. Elemental analysis - calculated for C6H15OClCu: C 27.18; H 5.70; found: C 26.86; H, 5.57. Anhydrous copper(I) chloride (1.04 g, 10.51 mmol, 1 equivalent) was added to a 250 mL round-bottom flask containing degassed DCPD ULTRENE 99-6 (100 g, 756 mmol, 72 equivalents). The reaction was carried out under argon atmosphere for 90 minutes at 100°C. A hot, greenish reaction mixture was filtered through Celite. A clear, colorless filtrate was left in the fridge (5°C) overnight. A white precipitate formed from the filtrate overnight. The white solid was filtered off on a sintered funnel and washed with isopropanol. The product was dried using a vacuum pump for several hours. 1.78 g white powder was obtained, 73% yield. Elemental analysis - calculated for C10H12ClCu: C 51.95; H 5.23; found: C 50.94; H 5.30. All reactions were carried out under argon atmosphere. The material hardness was examined with a Shore D-type durometer. The exothermic peak temperature was measured by a universal meter (with a thermocouple). 10 g of DCPD was placed in a 20 ml vial. A solution of respective (pre)catalyst (C = 25 mg/mL, DCM, 20 mol ppm with respect to the monomer) was then added. Further, the respective activator selected from 1a1, las, 1b1 and 1b2 (C = 25 mg/mL, DCM, 40 mol ppm, 2 molar equivalents to catalyst) was added. The vial contents were thoroughly mixed and argonated. The vial with formulation was capped and placed into an oil bath.
Use of the (pre)catalyst-activator system allows for obtaining hardened materials which cannot be obtained using (pre)catalysts alone. It has been also proven that the 1b2 complex (used as a catalyst) does not make the monomer polymerize at 60 °C as well as at 90 °C. 10 g of DCPD was placed in a 20 ml vial. A solution of the UltraLatMet (pre)catalyst (C = 25 mg/mL, DCM, 20 mol ppm with respect to the monomer) was then added. Optionally, a DMAP solution (C = 25 mg/mL, DCM, 40 mol ppm, 2 equivalents with respect to the catalyst) was also added. A DCM solution of respective activator selected from 1a1-1a5 was then added. The formulation components were thoroughly mixed. A thermocouple tip was inserted into the middle of the liquid. The vial with the formulation was argonated and capped. Polymerization was carried out at room temperature or at elevated temperatures in an oil bath. The results are shown in the table below. Use of activators - copper complexes according to the invention, in a concentration exceeding 10 ppm (except for 1a5 in combination with 4-DMAP) led to obtaining a material with a hardness lower than reported in the literature (approx. 82, Schore's D Scale). 4-DMAP as a polymerization retardant is compatible with the activators tested - copper complexes. A change in the activator concentration has a greater impact on curing time than gelling time. The type and concentration of the copper complex is, along with the polymerization temperature (room temperature/oil bath temperature) and the retardant presence, a factor allowing to control gelling time and curing time. 100 g of DCPD was added to a round-bottomed flask (250 ml), followed by the addition of a solution of UltraLatMet in DCM (25 mg/mL), so that the final concentration of UltraLatMet was 20 ppm (molar parts calculated with respect to DCPD). The flask contents were mixed thoroughly to obtain the formulation no. 1. 50 g of the resulting solution was transferred to a round-bottom flask (100 mL) and a DMAP solution in DCM (50 mg/mL) was added so that the final DMAP concentration was 40 mol ppm - the formulation no. 2. 10 g of solution was taken from each formulation and transferred to separate vials (20 mL), which were heated in an oil bath at 95°C until the polymerized material was obtained (approx. 25-35 minutes). A solution of UltraLatMet in DCM (25 mg/mL), a solution of DMAP in DCM (50 mg/mL) and a solution of 1b1 in DCM (50 mg/mL) were successively added to a round-bottom flask (100 mL). The flask contents were mixed and then the solvent was quickly evaporated by purging the flask with argon stream. A thin layer of brown-red sediment was formed on the walls of the flask. 50 g DCPD was added to the flask and the contents were mixed until the previously formed sediment layer was completely dissolved. Mixing was carried out under protective argon atmosphere. In the resulting solution, the final concentrations of the catalytic system components, i.e. UltraLatMet, DMAP and 1b1 were 28, 200 and 79 ppm (molar), respectively. 10 g of the solution obtained thereby was transferred to a vial (20 mL), which was heated in an oil bath at 80 °C for about 20 minutes until polymerized material was obtained. Material obtained from the formulation 3, i.e. using the activation method according to of the invention, is characterized by a glass-transition temperature of approx. 20-30°C higher than the material obtained with no activator addition. Using the activator allowed to achieve a much higher tensile strength value of the synthesized polymer. It is worth noting that UltraLatMet does not polymerize at 90°C (Table 1) but initiates polymerization at 95°C (Table 3). This is not a mistake but rather its specific feature, that raising the temperature by just 5°C results in thermal activation of this (pre)catalyst. Use of compounds selected from
- copper complexes having at least one organic ligand, or - ruthenium complexes having at least one organic ligand The use according to claim 1, wherein the copper complexes being the activators of olefin metathesis ruthenium (pre)catalysts have the structure described by a general formula 1a: X is an anionic ligand selected from a halogen atom, -CN, -SCN, -OR', -SR', -O(C=O)R', -O(SO2)R' or -OSi(R')3 group, wherein R' is a C1-C12 alkyl, C3-C12 cycloalkyl, C2-C12 alkenyl or C5-C20 aryl; L is independently a neutral ligand selected independently from cyclooctadiene, dicyclopentadiene and a P(R')3 group, wherein each R' may be the same or different and denotes C1-C12 alkyl, C3-C12 cycloalkyl, C5-C20 aryl, C2-C12 alkoxy, C5-C24 aryloxy or C3-C12 heteroaryl, and R' groups may interconnect with each other via carbon atoms forming a 3-12 membered ring; whereby the neutral L ligands may interconnect with each other, forming bidentate or tridentate ligands; or L is a neutral ligand defined by a general formula 4a, 4b or 4c:
wherein: each of R3 and R4 is independently C1-C12 alkyl, C3-C12 cycloalkyl, C5-C20 aryl or C5-C20 heteroaryl, which may be substituted independently with one and/or more substituents selected from the group comprising C1-C12 alkyl, C1-C12 perhaloalkyl, C1-C12 alkoxy, C5-C24 aryloxy, C5-C20 heteroaryloxy or a halogen atom; each of R5, R6, R7, R8, R9, R10 is independently a hydrogen atom, C1-C12 alkyl, C3-C12 cycloalkyl, C5-C20 aryl or C5-C20 heteroaryl, optionally substituted with at least one C1-C12 alkyl, C1-C12 perhaloalkyl, C1-C12 alkoxy or a halogen atom, and the R5, R6, R7, R8, R9, R10 groups may optionally interconnect with each other forming a C4-C10 cyclic or a C4-C12 polycyclic system, while ruthenium complexes being activators of olefin metathesis ruthenium (pre)catalysts have the structure described by a general formula 1b: / is 0 or 1; each of X1 and X2 is independently an anionic ligand; each of L1 and L2 is independently a P(R')3 group, wherein each R' may be the same or different and is C1-C12 alkyl, C3-C14 cycloalkyl, C5-C14 aryl or C3-C12 heteroaryl, and R' groups may interconnect with each other via carbon atoms forming a 3-12 membered ring; or L1 and/or L2 ligands may connect with each other forming a bidentate ligand defined by general formulae 5a or 5b:
wherein:
each of R13 and R14 is independently a hydrogen atom, C1-C12 alkyl, C3-C14 cycloalkyl or C5-C14 aryl, optionally substituted with at least one C1-C5 alkyl, C3-C6 cycloalkyl, C5-C14 aryl or halogen atom; or L2 ligand is a carbene ligand of the structure:
or each of L1 and L2 is independently a neutral ligand selected from benzene, p-cymene, mesitylene and cyclooctadiene. The use according to claim 1 or 2, wherein the copper complexes being the activators of olefin metathesis ruthenium (pre)catalysts have the structure defined by a general formula 1a: X is independently an anionic ligand selected from a halogen atom, -O(C=O)R', -OR' or - SR' group, wherein R' is a C1-C12 alkyl, a C5-C20 aryl; L is independently a neutral ligand selected independently from cyclooctadiene, dicyclopentadiene and a P(R')3 group, wherein each R' may be the same or different and is C1-C12 alkyl, C3-C12 cycloalkyl, C5-C20 aryl, C2-C12 alkoxy, C5-C24 aryloxy or C3-C12 heteroaryl, and whereby R' groups may interconnect with each other via carbon atoms forming a 3-12 membered ring; where the neutral L ligands may interconnect with each other, forming bidentate or tridentate ligands; or L is a neutral ligand defined by general formulae 4a or 4b:
wherein:
each of R3 and R4 is independently C1-C12 alkyl, C3-C12 cycloalkyl, C5-C20 aryl or C5-C20 heteroaryl, which may be substituted independently with one and/or more substituents selected from the group comprising C1-C12 alkyl, C1-C12 perhaloalkyl, C1-C12 alkoxy, C5-C24 aryloxy, C5-C20 heteroaryloxy or a halogen atom; each of R5, R6, R7, R8, R9, R10 is independently a hydrogen atom, C1-C12 alkyl, C3-C12 cycloalkyl, C5-C20 aryl or C5-C20 heteroaryl, optionally substituted with at least one C1-C12 alkyl, C1-C12 perhaloalkyl, C1-C12 alkoxy or a halogen atom, and the R5, R6, R7, R8, R9, R10 groups may optionally interconnect with each other forming a C4-C10 cyclic or a C4-C12 polycyclic system, while the ruthenium complexes being the activators of olefin metathesis ruthenium (pre)catalysts have the structure defined by a general formula 1b: each of X1 and X2 is independently a halogen atom, -O(C=O)R' group, wherein R' is C1-C12 alkyl, C3-C14 cycloalkyl or C5-C14 aryl, and wherein R' is optionally substituted with at least one C1-C5 alkyl, C3-C6 cycloalkyl, C5-C14 aryl or a halogen atom; or each of X1 and X2 is independently an anionic ligand defined by general formulae 6a, 6b and 6c:
wherein:
R15 is a hydrogen atom, C1-C12 alkyl, C3-C14 cycloalkyl, C5-C14 aryl, -(C=O)R' group or -O(C=O)R' group, wherein R' is C1-C12 alkyl, C3-C14 cycloalkyl or C5-C14 aryl, whereby R15 is optionally substituted with at least one C1-C5 alkyl, C3-C6 cycloalkyl, C5-C14 aryl or a halogen atom; or X1 and X2 are a bidentate anionic ligand defined by a general formula 7a:
wherein:
each of R16, R17, R18, R19, R20, R21, R22 is independently a hydrogen atom, C1-C12 alkyl, C3-C14 cycloalkyl, C5-C14 aryl or halogen atom; whereby each of R16, R17, R18, R19, R20, R21, R22 is optionally substituted with at least one C1-C5 alkyl, C3-C6 cycloalkyl, C5-C14 aryl or a halogen atom; each L1 and L2 is independently a P(R')3 group, wherein each R' can be the same or different and is C1-C12 alkyl, C3-C14 cycloalkyl, C5-C14 aryl or C3-C12 heteroaryl, and whereby R' groups may interconnect each other via carbon atoms forming a 3-12 membered ring, or L2 ligands may connect with each other forming a bidentate ligand defined by general formulae 5a or 5b:
wherein:
each of R13 and R14 is independently a hydrogen atom, C1-C12 alkyl or C5-C14 aryl, which may be independently substituted with one and/or more substituents selected from the group comprising C1-C5 alkyl, C3-C6 cycloalkyl or C5-C14 aryl; or L2 ligand is a carbene ligand having the structure:
or each L1 and L2 is independently a neutral ligand selected from benzene and cyclooctadiene. The use according to any of claims 1-3, wherein the copper complexes being the activators of olefin metathesis ruthenium (pre)catalysts have the structure described by a general formula 1a: X is a halogen atom, L is independently a neutral ligand selected independently from cyclooctadiene, dicyclopentadiene and a P(R')3 group, wherein each R' may be the same or different and is C1-C12 alkyl, C3-C12 cycloalkyl or C5-C20 aryl, and whereby R' groups may interconnect with each other via carbon atoms forming a 3-12 membered ring; whereby neutral ligands L may interconnect with each other forming bidentate or tridentate ligands; or L is a neutral ligand defined by a general formula 4a:
wherein:
each of R3 and R4 is independently C5-C20 aryl, optionally substituted with at least one C1-C12 alkyl; each of R5, R6, R7, R8 is independently a hydrogen atom; while the ruthenium complexes being the activators of olefin metathesis ruthenium (pre)catalysts have the structure defined by a general formula 1b: each of X1 and X2 is independently a halogen atom, -O(C=O)R' group or -O(C=O)R' group, wherein R' is C1-C12 alkyl, C3-C14 cycloalkyl or C5-C14 aryl, whereby R' is optionally substituted with at least one C1-C5 alkyl, C3-C6 cycloalkyl, C5-C14 aryl or a halogen atom; or each of X1 and X2 is independently anionic ligand described by general formula 6a:
wherein:
R15 is a hydrogen atom, C1-C12 alkyl, C3-C14 cycloalkyl, C5-C14 aryl or a -O(C=O)R' group, wherein R' is C1-C12 alkyl, C3-C14 cycloalkyl or C5-C14 aryl, whereby R15 is optionally substituted with at least one C1-C5 alkyl, C3-C6 cycloalkyl, C5-C14 aryl, or a halogen atom; or X1, X2 are a bidentate anionic ligand defined by a general formula 7a:
wherein:
each of R16, R17, R18, R19, R20, R21, R22 is independently a hydrogen atom, C1-C12 alkyl or halogen atom; each of L1 and L2 is independently a P(R')3 group, wherein R' can be the same or different and is C1-C12 alkyl, C3-C14 cycloalkyl, C5-C14 aryl or C3-C12 heteroaryl, and whereby R' groups may interconnect with each other via carbon atoms forming a 3-12 membered ring, or L2 ligands may connect with each other forming a bidentate ligand described by a general formula 5a:
wherein:
each of R13 and R14 is independently a hydrogen atom, C1-C12 alkyl or C5-C14 aryl, which may be independently substituted with one and/or more substituents selected from the group comprising C1-C5 alkyl, C3-C6 cycloalkyl and C5-C14 aryl; or one of the L1 or L2 ligands is a carbene ligand having the structure:
or each of L1 and L2 is independently cyclooctadiene. The use according to any of claims 1-4, wherein the activators have a structure represented by a structural formula selected from: The use according to any of claims 1-5, wherein the olefin metathesis ruthenium (pre)catalyst is described by a general formula 2, 3a, 3b, 3c 3d or 3e:
wherein:
each X1 and X2 is independently an anionic ligand selected from a halogen atom, -CN, -SCN, -OR', -SR', -O(C=O)R', -O(SO2)R' or -OSi(R')3 group, wherein R' is C1-C12 alkyl, C3-C12 cycloalkyl, C2-C12 alkenyl or C5-C20 aryl, which may be independently substituted with one and/or more substituents selected from the group comprising C1-C12 alkyl, C1-C12 perhaloalkyl, C1-C12 alkoxy, C5-C24 aryloxy, C5-C20 heteroaryloxy or a halogen atom; each R1 and R2 is independently a hydrogen atom, a halogen atom, C1-C25 alkyl, C1-C25 perhaloalkyl, C2-C25 alkenyl, C3-C7 cycloalkyl, C2-C25 alkenyl, C3-C25 cycloalkenyl, C2-C25 alkynyl, C3-C25 cycloalkynyl, C1-C25 alkoxy, C5-C24 aryloxy, C5-C20 heteroaryloxy, C5-C24 aryl, C5-C20 heteroaryl, C7-C24 aralkyl, C5-C24 perhaloaryl or a 3-12 membered heterocycle which may be independently substituted with one and/or more substituents selected from the group comprising a hydrogen atom, C1-C25 alkyl, C3-C7 cycloalkyl, C2-C25 alkenyl, C2-C25 cycloalkenyl, C1-C25 alkoxy, C5-C24 aryloxy, C5-C20 heteroaryloxy, C5-C24 aryl, C5-C20 heteroaryl or C7-C24 aralkyl; wherein R1 and R2 may be connected with each other forming a ring selected from C3-C7 cycloalkyl, C3-C25 cycloalkenyl, C3-C25 cycloalkynyl, C5-C24 aryl, C5-C20 heteroaryl, C5-C24 perhaloaryl, or a 3-12 membered heterocycle, which may be independently substituted with one and/or more substituents selected from the group comprising a hydrogen atom, a halogen atom, C1-C25 alkyl, C1-C25 perhaloalkyl, C3-C7 cycloalkyl, C2-C25 alkenyl, C3-C25 cycloalkenyl, C2-C25 alkynyl, C3-C25 cycloalkynyl, C1-C25 alkoxy, C5-C24 aryloxy, C5-C20 heteroaryloxy, C5-C24 aryl, C5-C20 heteroaryl, C7-C24 aralkyl, C5-C24 perhaloaryl or a 3-12 membered heterocycle, L3 is a neutral ligand defined by a general formula 4a, 4b or 4c:
wherein:
each of R3 and R4 is independently C1-C12 alkyl, C3-C12 cycloalkyl, C5-C20 aryl or C5-C20 heteroaryl, which may be substituted independently with one and/or more substituents selected from the group comprising C1-C12 alkyl, C1-C12 perhaloalkyl, C1-C12 alkoxy, C5-C24 aryloxy, C5-C20 heteroaryloxy or a halogen atom; each of R5, R6, R7, R8, R9, R10 is independently a hydrogen atom, C1-C12 alkyl, C3-C12 cycloalkyl, C5-C20 aryl or C5-C20 heteroaryl, optionally substituted with at least one C1-C12 alkyl, C1-C12 perhaloalkyl, C1-C12 alkoxy or a halogen atom, and the R5, R6, R7, R8, R9, R10 groups may optionally interconnect with each other forming a C4-C10 cyclic or a C4-C12 polycyclic system; Z is a P(R')3 group, wherein each R' can be the same or different and is C1-C12 alkyl, C3-C12 cycloalkyl, C5-C20 aryl or C3-C12 heteroaryl, and whereby R' groups may interconnect with each other via carbon atoms forming a 3-12 membered ring; or Z may be a neutral ligand; or Z may form bidentate and tridentate ligands; X1 Z R2 is a tridentate ligand; each of X1 Z, X2 Z and X1 R2 is independently a bidentate ligand. The use according to any of claims 1-6, wherein the olefin metathesis ruthenium (pre)catalyst is described by a general formula 2, 3a, 3b or 3c:
wherein:
each of X1 and X2 is independently an anionic ligand selected from a halogen atom, -OR' or -O(C=O)R' group, wherein R' is C1-C12 alkyl, C3-C12 cycloalkyl, C2-C12 alkenyl or C5-C20 aryl, which may be substituted independently with one and/or more substituents selected from the group comprising C1-C12 alkyl, C1-C12 perhaloalkyl, C1-C12 alkoxy, C5-C24 aryloxy, C5-C20 heteroaryloxy or a halogen atom; each of R1 and R2 is independently a hydrogen atom, C1-C25 alkyl, C3-C7 cycloalkyl, C2-C25 alkenyl, C3-C25 cycloalkynyl, C5-C24 aryl, C5-C20 heteroaryl, C7-C24 aralkyl or a 3-12 membered heterocycle that may be substituted independently with one and/or more substituents selected from the group comprising a hydrogen atom, C1-C25 alkyl, C3-C7 cycloalkyl, C2-C25 alkenyl, C3-C25 cycloalkenyl, C1-C25 alkoxy, C5-C24 aryloxy, C5-C20 heteroaryloxy, C5-C24 aryl, C5-C20 heteroaryl or C7-C24 aralkyl; wherein R1 and R2 may be connected with each other forming a ring selected from a group comprising C3-C7 cycloalkyl, C3-C25 cycloalkenyl, C5-C24 aryl or a 3-12 membered heterocycle which may be substituted independently with one and/or more substituents selected from the group comprising a hydrogen atom, C1-C25 alkyl, C3-C7 cycloalkyl, C2-C25 alkenyl, C3-C25 cycloalkenyl, C1-C25 alkoxy, C5-C24 aryloxy, C5-C20 heteroaryloxy, C5-C24 aryl, C5-C20 heteroaryl and C7-C24 aralkyl; L3 is a neutral ligand defined by a general formula 4a or 4b:
wherein:
each of R3 and R4 is independently C5-C20 aryl or C5-C20 heteroaryl, optionally substituted with at least one C1-C12 alkyl, C2-C12 alkoxy or a halogen atom; each of R5, R6, R7, R8, R9, R10 is independently a hydrogen atom, C1-C12 alkyl, C3-C12 cycloalkyl, C5-C20 aryl, or C5-C20 heteroaryl, optionally substituted with at least one C1-C12 alkyl, C1-C12 perhaloalkyl, C1-C12 alkoxy or a halogen atom, and the R5, R6, R7, R8, R9, R10 groups may optionally interconnect with each other forming a C4-C10 cyclic or a C4-C12 polycyclic system; Z is a P(R')3 group, wherein each R' may be the same or different and is C1-C12 alkyl, C3-C12 cycloalkyl or C5-C20 aryl; X2 Z is a bidentate ligand defined by a formula:
wherein:
each of R11 and R12 is independently a hydrogen atom, a halogen atom, C1-C16 alkyl, C1-C6 alkoxy, C1-C16 perhaloalkyl, C3-C7 cycloalkyl, C2-C16 alkenyl, C6-C14 aryl, C6-C14 perhaloaryl, C3-C12 heterocycle, -OR', -NO2, -COOH, -COOR', -CON(R')(R"), -SO2N(R')(R"), -CHO or -COR' group, wherein each R' and R" is independently C1-C16 alkyl, C1-C16 perhaloalkyl, C6-C14 aryl or C6-C14 perhaloaryl; X1 R2 is a bidentate ligand defined by a formula:
wherein:
x is an integer from 0 to 4; R11 is independently a hydrogen atom, a halogen atom, C1-C16 alkyl, C1-C6 alkoxy, C1-C16 perhaloalkyl, C3-C7 cycloalkyl, C2-C16 alkenyl, C6-C14 aryl, C6-C14 perhaloaryl, C3-C12 heterocycle, -OR', -NO2, -COOH, -COOR', -CON(R')(R"), -SO2N(R')(R"), -CHO or -COR' group, wherein each R' and R" is independently C1-C16 alkyl, C1-C16 perhaloalkyl, C6-C14 aryl or C6-C14 perhaloaryl; X1 Z R2 is a tridentate ligand defined by a formula:
wherein:
x is an integer from 0 to 4; R11 is independently a hydrogen atom, a halogen atom, C1-C16 alkyl, C1-C6 alkoxy, C1-C16 perhaloalkyl, C3-C7 cycloalkyl, C2-C16 alkenyl, C6-C14 aryl, C6-C14 perhaloaryl, C3-C12 heterocycle, -OR', -NO2, -COOH, -COOR', -CON(R')(R"), -SO2N(R')(R"), -CHO or -COR' group, wherein each R' and R" is independently C1-C16 alkyl, C1-C16 perhaloalkyl, C6-C14 aryl or C6-C14 perhaloaryl; each of R23 and R24 is independently a hydrogen atom, a halogen atom, C1-C16 alkyl, C1-C6 alkoxy, C3-C7 cycloalkyl or C6-C14 aryl. The use according to any of claims 1-7, wherein the olefin metathesis ruthenium (pre)catalyst is defined by a general formula 2, 3a, 3b or 3c:
wherein:
X1, X2, R1, R2, Z, R11, R12, R23, R24, x are as defined in claim 7; L3 is a neutral ligand defined by a general formula 4a or 4b:
wherein:
each of R3 and R4 is independently C5-C20 aryl or C5-C20 heteroaryl, optionally substituted with at least one C1-C12 alkyl, C2-C12 alkoxy or a halogen atom; each of R5, R6, R7, R8, R9, R10 is independently a hydrogen atom, C1-C12 alkyl, C3-C12 cycloalkyl, C5-C20 aryl or C5-C20 heteroaryl, optionally substituted with at least one C1-C12 alkyl, C1-C12 perhaloalkyl, C1-C12 alkoxy or halogen atom, and the R5, R6, R7, R8, R9, R10 groups may optionally interconnect with each other forming a C4-C10 cyclic or a C4-C12 polycyclic system. The use according to claim 8, wherein the metathesis ruthenium (pre)catalyst 2 has the structure defined by a general formula 2a or 2b:
wherein:
X1, X2, R1, R2, R3, R4 are as defined in claim 7; y is a number from 0 to 5; R25 is independently C1-C12 alkyl, C2-C12 alkoxy or a halogen atom; each of R7, R8, R9, R10 is independently a hydrogen atom, C1-C12 alkyl, C3-C12 cycloalkyl, C5- C20 aryl or C5-C20 heteroaryl, optionally substituted with at least one C1-C12 alkyl, C1-C12 perhaloalkyl, C1-C12 alkoxy or a halogen atom, and the R7, R8, R9, R10 groups may optionally interconnect with each other forming a C4-C10 cyclic or a polycyclic C4-C12 system. The use according to claim 8, wherein the olefin metathesis ruthenium (pre)catalyst 2 has the structure defined by a general formula 2a:
wherein:
X1, X2, R1, R2 are defined in claim 7; y is an integer from 1 to 5; R25 is independently C1-C12 alkyl or a halogen atom; each of R7, R8, R9, R10 is independently a hydrogen atom, C1-C12 alkyl, C3-C12 cycloalkyl or C5-C20 aryl, optionally substituted with at least one C1-C12 alkyl, C1-C12 perhaloalkyl or a halogen atom, and the R7, R8, R9, R10 groups may optionally interconnect with each other forming a C4-C10 cyclic or a C4-C12 polycyclic system. The use according to any of claims 1-10, wherein the olefin metathesis ruthenium (pre)catalyst has a structure represented by a structural formula selected from:
The use according to any of claims 1-11, wherein the reaction is carried out with no solvent. The use according to any of claims 1-12, wherein the catalyst is added in a solid form and/or in form of a solution in an organic solvent, in an amount not higher than 100 ppm. The use according to any of claims 1-13, wherein the activator is added in a solid form and/or in form of a solution in an organic solvent, in an amount not higher than 1000 ppm. The use according to any of claims 1-14, wherein 4-dimethylaminopyridine in a solid form and/or in form of a solution in an organic solvent is added to the catalyst-activator system in an amount of not higher than 500 ppm.
(CuX
wherein:
(RuX1
wherein:
(CUX
wherein:
(RUX1
wherein:
(CuX
wherein:
(RUX1
wherein:
R15 is a hydrogen atom, C1-C12 alkyl, C3-C14 cycloalkyl, C5-C14 aryl or a -O(C=O)R' group, wherein R' is C1-C12 alkyl, C3-C14 cycloalkyl or C5-C14 aryl, whereby R15 is optionally substituted with at least one C1-C5 alkyl, C3-C6 cycloalkyl, C5-C14 aryl, or a halogen atom; or X1, X2 are a bidentate anionic ligand defined by a general formula 7a:
wherein:
The term Embodiments of the invention
1. Structures of activators and (pre)catalysts
[CuCl(PPh3)1.5] 1a1
[CuCI(DCPD)] 1a4
has been verified with (pre)catalysts having the structures illustrated below:
2. Experimental part
2.1 Synthesis of activators
[CuCl(PPh3)1.5] (1a1):
[CuCl(P(OEt)3)] (1a2):
[CuCI(DCPD)] (1a4):
2.2. Test polymerization reactions
2.2.1 Example I
Karb-I none No gelling No curing 65 Karb-I 1b1 07:00 15:00 65 LatMet none 75:00 No curing after 24 h 65 LatMet 1a5 17:40 60:00 65 LatMet-SiPr none 95:00 No curing 65 LatMet-SiPr las 27:00 No curing after 5 h 65 LatMet-SiPr none 60:00 No curing 90 LatMet-SiPr 1a5 13:20 No curing after 5 h 90 LatMet-I none No gelling after 3 h No curing 65 LatMet-I 1a5 27:00 2h 65 LatMet-3D3 none No gelling No curing 65 LatMet-3D3 1b1 10:00 15:00 65 UltraLatMet none No gelling after 40 min No curing 65 UltraLatMet 1b2 11:00 No curing after 5 h 65 UltraLatMet none No gelling No curing 90 UltraLatMet 1b2 4:00 14:30 90 UltraLatMet 1b3 3:30 9:00 90 UltraLatMet 1b4 3:30 10:00 90 UltraLatMet 1b5 5:00 16:00 90 Gru-CAAC none 30:00 No curing 65 Gru-CAAC 1a1 1:00 2:00 65 none 1b2 No gelling after 40 min No curing 65 none 1b2 No gelling No curing 90 * Time counted from placing the vial with formulation into an oil bath 2.2.2 Example II
1a1 2 - 00:50 3:40 RT 186 84.8 1a1 4 - 00:50 03:10 RT 196 86.4 1a17 - 00:55 02:30 RT 196 85.8 1a1 20 - 01:05 02:40 RT 178 79.4 1a1 2 + 02:00 07:10 65 211 85.0 1a1 4 + 01:30 04:10 65 213 83.4 1a1 7 + 01:15 02:40 65 212 80.2 1a1 15 + 01:20 03:00 65 193 73.4 1a2 3 - 01:05 04:00 RT 192 85.4 1a2 5 - 01:00 02:50 RT 197 86.4 1a2 10 - 00:50 02:30 RT 195 86.2 1a2 20 - 00:50 02:30 RT 162 74.8 1a2 3 + 01:40 04:30 65 209 84.8 1a2 5 + 01:45 03:40 65 211 82.2 1a2 10 + 01:40 02:50 65 205 82.0 1a2 20 + 01:20 02:40 65 182 40.0 1a3 5 - 00:40 02:10 RT - 87.1 1a3 230 2 equiv. - - RT - 64.0 1a3 10 6 equiv. - - 90 180 50.0 1a4 2 - 00:50 - RT - 87.0 1a4 5 - 00:25 01:00 RT - 87.0 1a4 20 - 00:38 02:20 RT - 77.0 1a5 20 - 00:40 8:40 80 206 75.0 1a4 20 + 3:00 12:10 80 206 82.0 * Time counted from adding the activator or from inserting the formulation vial into the oil bath in the event of reactions carried out at elevated temperature. 2.2.3 Example III
Formulation 1 and 2
Formulation 3
Oil bath temperature [°C] 95 95 80 Glass-transition temperature Tg [°C] 152±12 142:1:13 171±5 Curing time 22:20:1:10 31:50±2:45 18:50±1:10 Temperature peak [°C] 221±2 215±3 221±2 Hardness (Shore D scale) 80-85 75-83 88.3±0.2 Tensile strength 38.8±1.9 35.1±6.5 55.0±0.2 Young's modulus 1.87±0.13 1.95±0.19 1.87±0.06 Storage time at 20 °C* 11 h 180 h 3 weeks * Storage time at 20 °C is "shelf time" (or pot life), i.e. the period for which a formulation can be stored before getting so thick that it cannot be used again, or before the catalyst decomposes. 3. Literature
(CuX
wherein:
(RuX1
wherein:
(CuX
wherein:
(RuX1
wherein:
(CuX
wherein:
(RuX1
wherein:
[CuCl(PPh3)1.5] 1a1
[CuCl(DCPD)] 1a4
CPC - классификация
BB0B01B01JB01J2B01J22B01J223B01J2231B01J2231/B01J2231/5B01J2231/54B01J25B01J253B01J2531B01J2531/B01J2531/1B01J2531/16B01J2531/8B01J2531/82B01J2531/821CC0C08C08FC08F1C08F10C08F10/C08F10/0C08F10/00C08F2C08F2/C08F2/0C08F2/06C08F4C08F4/C08F4/5C08F4/50C08GC08G2C08G22C08G226C08G2261C08G2261/C08G2261/1C08G2261/13C08G2261/135C08G2261/3C08G2261/33C08G2261/332C08G2261/3325C08G2261/4C08G2261/41C08G2261/418C08G2261/7C08G2261/76C08G6C08G61C08G61/C08G61/0C08G61/08Цитирование НПИ
ANNA SZADKOWSKA ET AL: "Ruthenium Olefin Metathesis Initiators Bearing Chelating Sulfoxide Ligands", ORGANOMETALLICS, vol. 28, no. 9, 11 May 2009 (2009-05-11), pages 2693-2700, XP055465563, US ISSN: 0276-7333, DOI: 10.1021/om801183gWO-A1-2012/168183
WO-A1-2014/144634
WO-A1-2017/187434